Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Senti Biosciences's share price for the quarter that ended in Mar. 2024 was $0.3771. Senti Biosciences's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 45.71 Mil. Therefore, Senti Biosciences's market cap for the quarter that ended in Mar. 2024 was $17.24 Mil.
Senti Biosciences's quarterly market cap
increased
from Sep. 2023 ($18.37 Mil) to Dec. 2023 ($30.16 Mil) but then
declined
from Dec. 2023 ($30.16 Mil) to Mar. 2024 ($17.24 Mil).
Senti Biosciences's annual market cap
increased
from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($62.13 Mil) but then
declined
from Dec. 2022 ($62.13 Mil) to Dec. 2023 ($30.16 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Senti Biosciences's Enterprise Value for Today is $30.16 Mil.
Senti Biosciences Market Cap Historical Data
The historical data trend for Senti Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Senti Biosciences's Market Cap
For the Biotechnology subindustry, Senti Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Senti Biosciences's Market Cap falls into.
Senti Biosciences Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Senti Biosciences's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences (NAS:SNTI) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Senti Biosciences Market Cap Related Terms
Thank you for viewing the detailed overview of Senti Biosciences's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Senti Biosciences (Senti Biosciences) Business Description
Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SNTI has been successfully added to your 